Dr. Lal PathLabs Beheer

Beheer criteriumcontroles 2/4

De CEO Dr. Lal PathLabs' is Shankha Banerjee, benoemd in May2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.027% van de aandelen van het bedrijf, ter waarde ₹ 76.03M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 5.5 jaar.

Belangrijke informatie

Shankha Banerjee

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	4.5yrs
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Recent updates

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

May 25

CEO

Shankha Banerjee

less than a year

Tenure

Mr. Shankha Banerjee serves as Chief Executive Officer of Group & Associates Companies at Dr. Lal PathLabs Limited. He served as Chief Operating Officer at Dr. Lal PathLabs Limited since 2020. He had been...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Arvind Lal	Executive Chairman	29.7yrs	₹30.14m	32.93% ₹ 86.1b
Om Manchanda	MD & Director	4.5yrs	₹46.45m	1.04% ₹ 2.7b
Vandana Lal	Executive Director	no data	₹24.18m	19.3% ₹ 50.5b
Shankha Banerjee	Chief Executive Officer	less than a year	geen gegevens	0.027% ₹ 69.8m
Ved Goel	Group CFO & CEO of International Business	6.2yrs	₹7.30m	0.014% ₹ 37.8m
Jai Meena	Chief Operating Officer	2.5yrs	geen gegevens	geen gegevens
Munender Soperna	Chief Information & Digital Officer	10.3yrs	geen gegevens	0.025% ₹ 65.6m
Vinay Gujral	Company Secretary & Compliance Officer	1.5yrs	geen gegevens	0.00066% ₹ 1.7m
Manoj Garg	Group Chief Human Resources Officer	10yrs	geen gegevens	0.033% ₹ 85.3m

4.5yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LALPATHLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Arvind Lal	Executive Chairman	29.7yrs	₹30.14m	32.93% ₹ 86.1b
Om Manchanda	MD & Director	13.7yrs	₹46.45m	1.04% ₹ 2.7b
Vandana Lal	Executive Director	29.7yrs	₹24.18m	19.3% ₹ 50.5b
Arun Duggal	Lead Independent Director	1.7yrs	₹3.85m	geen gegevens
Rajit Mehta	Independent Director	1.3yrs	₹1.56m	geen gegevens
Rahul Sharma	Non Executive Director	19.3yrs	₹2.65m	0.024% ₹ 62.8m
Rohit Bhasin	Independent Non-Executive Director	1.9yrs	₹2.60m	geen gegevens
Somya Satsangi	Independent Director	5.7yrs	₹2.70m	geen gegevens
Archana Erdmann	Non-Executive Director	5.4yrs	₹2.25m	1.85% ₹ 4.8b
Gurinder Singh Kalra	Independent Director	1.3yrs	₹1.56m	geen gegevens

5.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LALPATHLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Dr. Lal PathLabs Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

MD & Director recently sold ₹28m worth of stock

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Recent updates

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

MD & Director recently sold ₹28m worth of stock

Price target increased by 12% to ₹2,924

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

MD & Director recently sold ₹41m worth of stock

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?